Key Publications November 9, 2021
The efficacy, safety and tolerability of Circadin® have been reported in several key publications.
In this section you will find a list of the major publications. Please note that Circadin® is indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over. Accordingly, the off label use which may be indicated in the articles below is not recommended by Neurim and the prescribing and labelling of your country must be followed.

To view an abstract, simply click on the title of the publication.


Circadin® in mental disorders and conditions

Circadin® in children

Circadin® in diabetes

Circadin® in hypertension

  • News & Views

    • Dr. Zach Pearl Staff

    • November, 2022
    • Circadian Rhythm Sleep Disorders
    • Read More